ADC Linker i.e. Antibody-DrugConjugate (ADC) is a biologically active small molecule drug coupled to a monoclonal antibody (monoclonal antibody) via a linker. Antibody-drug couplers are an important form of drugs that play an important role in areas such as tumor therapy and drug delivery, while linkers are the chemical components that connect the antibody to the drug.

The role of linker in ADC is as follows:

1. Connecting antibody and drug

Linkers are able to determine the connection sites between drugs and antibodies and achieve stable binding through specific connections. The selectivity and specificity of linker can make the connection between drug and antibody strong and lasting, thus ensuring accurate drug delivery and targeted therapy.

2. Improve drug stability

Certain drugs may be easily degraded or inactivated in vivo, and linkers can be structurally adjusted or chemically modified to protect the drug and extend its half-life and efficacy in vivo. In addition, linkers can also improve the affinity between the drug and the antibody, enhance the stability and biological activity of the drug on the surface of the antibody.

3. Better drug release

ADCLinker can regulate the rate and pattern of drug release by targeted and non-targeted means. For example, certain linkers can achieve orderly release of drugs according to external stimuli or changes in the internal cellular environment, which mainly refers to, for example, pH, temperature, or enzyme effects, and the role of the linker is to improve the local therapeutic effect of the drug.

4. Improve biocompatibility

The choice of linker can also affect the biocompatibility and toxicity of antibody-drug couplings. The linker should have lower immunogenicity and toxicity to reduce the risk of human immune response and adverse reactions. In addition, the linker should also have a low binding affinity and a high binding speed to ensure rapid absorption and distribution of the drug in the body.

In summary, ADCLinker is a key component in antibody-drug coupling compounds that connects the antibody and the drug. In order to improve the targeting, stability and efficacy of antibody-drug couplers, the linker must be rationally selected and designed. Therefore, the study and optimization of linkers are of great significance for the development of more effective antibody-drug couplers, which can also better guarantee the efficacy and controllability of drugs.